Pennine Health Talks Sustainability Compliance and ESG Initiatives by Citeline

Pink Sheet reporter and editors discuss a new pilot project allowing collaborative reviews of gene therapies by multiple regulators (:42), predictions for the upcoming year by current and former US FDA leaders (11:12), and the FDA commissioner’s take on artificial intelligence (21:23).

More On These Topics From The Pink Sheet

Don’t Call It Project Orbis: CoGenT Global Will Pilot Collaborative Review Of Gene Therapies: https://pink.citeline.com/PS149607/Dont-Call-It-Project-Orbis-CoGenT-Global-Will-Pilot-Collaborative-Review-Of-Gene-Therapies

EMA To Become Observer Of FDA’s Project Orbis Early This Year: https://pink.citeline.com/PS149579/EMA-To-Become-Observer-Of-FDAs-Project-Orbis-Early-This-Year

New Year’s Predictions From FDA Leadership Past And Present: GLP-1s, Mental Health, Big Data: https://pink.citeline.com/PS149583/New-Years-Predictions-From-FDA-Leadership-Past-And-Present-GLP1s-Mental-Health-Big-Data

US FDA’s Role In Artificial Intelligence/Machine Learning Development Is ‘Convener,’ Califf Says: https://pink.citeline.com/PS149608/US-FDAs-Role-In-Artificial-IntelligenceMachine-Learning-Development-Is-Convener-Califf-Says

In the latest episode of the In Vivo podcast, non-executive chair Peter Bains and Owain Millington, vice president of immunology and head of preclinical, discuss ILC Therapeutics’ platform technology, financing plans as well as the pros and cons of running a startup biotech in the UK.

Join Jung Won Shin for this Korean-language mini podcast talking about a report from Citeline's Datamonitor Healthcare.

Datamonitor Healthcare의 비만치료제시장 분석리포트를 요약한 내용입니다.

https://www.biomedtracker.com/reportdetail.cfm?reportid=863

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: 2023 drug launch highlights; the M&A outlook for the new year; AstraZeneca’s China cell therapy acquisition; the pre-Christmas deal flow; and India at a turning point for ADCs?

https://scrip.citeline.com/SC149606/Quick-Listen-Scrips-Five-MustKnow-Things

Listen as Chris Smyth, President, ICON Biotech Solutions discusses current trends in the biotech landscape, and predictions for future innovation, regulation and globalisation in this space. Recorded on Wednesday 15th November.

One week into 2024, there have already been multiple deals between Chinese innovative drug developers and multinational and the significant acquisition of GracellBio by AstraZeneca. Brian Yang and Dexter Yan invite guest speaker Liu Liu to discuss reasons behind the particularly active deal-making scene in the China biotech sector.

https://scrip.citeline.com/SC149598/Chinese-Language-Podcast--AZMNC2024

In this edition of Cardio Conversations, Medtech Insight editor Reed Miller talked to Robert Chisena, the co-founder and CTO of AVS. He talked about the company's novel interventional technology for calcified peripheral arterial disease and how the company came together during the pandemic.

Further Reading

https://medtech.citeline.com/MT148128/Shockwave-Begins-First-All-Female-Study-Of-Coronary-Interventions

https://medtech.citeline.com/MT147704/Reimbursement-For-Shockwaves-IVL-Device-May-Pose-Quandary-For-CMS

https://medtech.citeline.com/MT147623/Abbott-Buys-CSI-To-Add-Peripheral-And-Coronary-Atherectomy-Technologies

https://medtech.citeline.com/MT147548/Shockwave-Buys-Neovasc-Hoping-Reducer-Angina-Device-Complements-Coronary-Lithotripsy

https://medtech.citeline.com/MT143510/FDA-Approves-Shockwave-Coronary-Intravascular-Lithotripsy-System

Further Listening

The full recording of this podcast, as well as all of our other Citeline podcasts, are available on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn, Spotify Podcasts and via smart speakers if one of these platforms has been set up as your default podcast provider.

Pink Sheet reporter and editors discuss key US and EU legislation that impacted 2023 and how it also could affect 2024, including EU legislative reform (:56), US Medicare drug price negotiations (14:43), and the US Food and Drug Administration user fee reauthorization (30:57).

More On These Topics From The Pink Sheet

European Commission Explains Impact Of EU Pharma Review On SMEs & Non-Profit Entities: https://pink.citeline.com/PS149505/European-Commission-Explains-Impact-Of-EU-Pharma-Review-On-SMEs--NonProfit-Entities

Biopharma’s Prospects Under A Second Trump Term: They Can’t Get Much Worse: https://pink.citeline.com/PS149562/Biopharmas-Prospects-Under-A-Second-Trump-Term-They-Cant-Get-Much-Worse

The following special topic pages include links to all of our coverage:

EU Legislative Reform: https://pink.citeline.com/eu-legislative-reform

FDA User Fees: https://pink.citeline.com/us-fda-user-fees

Drug Pricing Debate: https://pink.citeline.com/pricing-debate

Join us for an insightful Q&A session with Dr. Vega, where we delve into the groundbreaking world of Multi-Cancer Early Detection (MCED) and the future of cancer detection.